Teladoc Inc (TDOC) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 34 from a previous price target of $36 . FBR Capital advised their investors in a research report released on Jul 20, 2016.
Many Wall Street Analysts have commented on Teladoc Inc. Company shares were Reiterated by Piper Jaffray on Jul 11, 2016 to “Overweight”, Firm has raised the Price Target to $ 22 from a previous price target of $20 .Teladoc Inc was Initiated by Piper Jaffray to “Overweight” on May 26, 2016.
On the company’s financial health, Teladoc Inc reported $-0.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.38. The company had revenue of $26.90 million for the quarter, compared to analysts expectations of $26.64 million. The company’s revenue was up 63.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-5.87 EPS.
Teladoc Inc opened for trading at $15.5 and hit $16.07 on the upside on Monday, eventually ending the session at $16.05, with a gain of 3.88% or 0.6 points. The heightened volatility saw the trading volume jump to 12,33,467 shares. Company has a market cap of $621 M.
In a different news, on Jul 15, 2016, Jason N Gorevic (President & CEO) sold 5,000 shares at $15.45 per share price. According to the SEC, on Jul 1, 2016, James K Outland (director) sold 10,000 shares at $15.00 per share price. On Mar 18, 2016, Dana G Jr. Mead (director) purchased 10,000 shares at $10.65 per share price, according to the Form-4 filing with the securities and exchange commission.
Teladoc Inc. is a telehealth company. The Company offers an on-demand healthcare platform through mobile devices Internet video and phone. Its solution connects consumers with physicians and behavioral health professionals or its providers who treat various conditions and cases from acute diagnoses such as upper respiratory infection urinary tract infection and sinusitis to dermatological conditions anxiety and smoking cessation. The Teladoc solution enables accessing on-demand healthcare for employers health plans and health systems. Its platform provides accessing physicians clinical programs and consumer engagement strategies. Its platform provides for interconnectivity between healthcare constituents. It offers solutions such as remote patient monitoring post-discharge treatment plan adherence and in-home and chronic care. Its customers also include channel partners such as brokers resellers and consultants who sell into a range of small medium and large enterprises.